Loading...
OTCMTLPPF
Market cap5.15bUSD
Dec 20, Last price  
15.90USD
1D
-0.63%
1Q
19.70%
IPO
1,358.72%
Name

Telix Pharmaceuticals Ltd

Chart & Performance

D1W1MN
OTCM:TLPPF chart
P/E
1,635.23
P/S
17.16
EPS
0.02
Div Yield, %
0.00%
Shrs. gr., 5y
9.88%
Rev. gr., 5y
379.89%
Revenues
497m
+210.23%
00000195,1423,485,0005,213,0007,596,000160,096,000496,659,000
Net income
5m
P
-289,000-497,000-132,000-44,000-6,377,115-13,829,825-27,867,000-44,887,000-80,510,000-104,079,0005,211,000
CFO
24m
P
00-6,031,515-20,747,664-23,333,0001,960,000-59,328,000-63,970,00023,884,000
Earnings
Feb 20, 2025

Profile

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
URL
https://telixpharma.com/
IPO date
Nov 15, 2017
Employees
234
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
496,659
210.23%
160,096
2,007.64%
7,596
45.71%
Cost of revenue
450,853
282,120
112,306
Unusual Expense (Income)
NOPBT
45,806
(122,024)
(104,710)
NOPBT Margin
9.22%
Operating Taxes
(2,124)
5,457
(18,529)
Tax Rate
NOPAT
47,930
(127,481)
(86,181)
Net income
5,211
-105.01%
(104,079)
29.27%
(80,510)
79.36%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,652
165,407
3,782
BB yield
-0.20%
-7.32%
-0.17%
Debt
Debt current
1,559
641
632
Long-term debt
24,158
9,805
3,814
Deferred revenue
22,522
23,056
Other long-term liabilities
76,097
61,807
43,226
Net debt
(109,780)
(100,364)
(17,591)
Cash flow
Cash from operating activities
23,884
(63,970)
(59,328)
CAPEX
(9,679)
(13,861)
(1,339)
Cash from investing activities
(25,489)
(16,997)
(2,726)
Cash from financing activities
10,186
174,960
2,846
FCF
36,275
(139,990)
(87,689)
Balance
Cash
123,237
116,329
22,037
Long term investments
12,260
(5,519)
Excess cash
110,664
102,805
21,657
Stockholders' equity
148,911
80,007
2,158
Invested Capital
131,789
83,111
70,305
ROIC
44.61%
ROCE
18.89%
EV
Common stock shares outstanding
323,710
310,644
282,206
Price
10.08
38.65%
7.27
-6.19%
7.75
105.03%
Market cap
3,262,997
44.48%
2,258,382
3.26%
2,187,096
124.90%
EV
3,153,217
2,158,018
2,169,506
EBITDA
52,730
(116,645)
(99,536)
EV/EBITDA
59.80
Interest
13,136
406
189
Interest/NOPBT
28.68%